Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population.

MSD has begun the randomised MOBILIZE-1 Phase III trial to assess the investigational quadrivalent vaccine, V181.

The relationship between neurodegenerative conditions and late-life mood disorders (LLMDs) is largely unexplored.

The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in ...

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

At the CTO West Coast conference, experts discussed the future of oncology clinical trials and key themes surrounding them.

HepaRegeniX has begun dosing subjects in a Phase Ib trial of HRX-215 in subjects undergoing partial liver resection due to ...

Industry experts gathered at the Outsourcing in Clinical Trials East Coast 2025 conference to discuss artificial intelligence ...

NewAmsterdam Pharma has reported encouraging topline data from a prespecified biomarker analysis of Alzheimer’s disease in a ...

Sobi and Apellis Pharmaceuticals have reported new results from the open-label period of the randomised Phase III VALIANT ...